Human antibodies to the 19kDa C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 inhibit parasite growth in vitro

Parasite Immunol. 1999 Mar;21(3):133-9. doi: 10.1046/j.1365-3024.1999.00209.x.


The 19kDa, C-terminal fragment of the major surface protein of Plasmodium falciparum (PfMSP1(19)) is a candidate for inclusion in a subunit malaria vaccine. In this study, we show that PfMSP1(19)-specific antibodies, affinity purified from malaria-immune human serum, can: (i) compete with invasion-inhibitory monoclonal antibodies for binding to PfMSP1(19) and (ii) mediate inhibition of parasite growth in vitro, in the absence of complement and mononuclear cells, at physiological antibody concentrations (100 micrograms/ml). Parasites expressing either the Kl or 3D7 allele of PfMSP1(19) were equally susceptible to inhibition of merozoite invasion, indicating that the target epitopes of inhibitory antibodies are conserved or cross-reactive. These studies suggest that vaccines designed to induce antibodies to PfMSP1(19) may protect against the high levels of malaria parasitaemia which are associated with clinical disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Animals
  • Antibodies, Monoclonal / immunology
  • Antibodies, Protozoan / immunology*
  • Antibodies, Protozoan / isolation & purification
  • Chromatography, Affinity
  • Enzyme-Linked Immunosorbent Assay
  • Humans
  • Malaria, Falciparum / immunology*
  • Merozoite Surface Protein 1 / immunology*
  • Plasmodium falciparum / growth & development
  • Plasmodium falciparum / immunology*


  • Antibodies, Monoclonal
  • Antibodies, Protozoan
  • Merozoite Surface Protein 1